Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Unaudited financial results (standalone and consolidated) pursuant to SEBI Listing Regulations
Audit Opinion:
Clean opinion - No modifications. The limited review report states: "nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement."
Key Financial Highlights [₹ in millions]:
Standalone Results:
Revenue from Operations: ₹4,277.30 (Q1 FY27) vs ₹2,780.26 (Q1 FY26) - 54% YoY increase
Total Income: ₹4,301.41 (Q1 FY27) vs ₹2,794.64 (Q1 FY26)
Net Profit: ₹824.49 (Q1 FY27) vs ₹351.52 (Q1 FY26) - 135% YoY increase
EPS: Basic ₹4.99, Diluted ₹4.94 (not annualized)
Other Equity: ₹13,367.64 (as of March 31, 2026)
Research and development expenditure: ₹596.76
Consolidated Results:
Revenue from Operations: ₹5,343.38 (Q1 FY27) vs ₹3,524.94 (Q1 FY26) - 52% YoY increase
Total Income: ₹5,400.21 (Q1 FY27) vs ₹3,531.27 (Q1 FY26)
Net Profit attributable to owners: ₹847.81 (Q1 FY27) vs ₹433.01 (Q1 FY26) - 96% YoY increase
EPS: Basic ₹5.13, Diluted ₹5.08 (not annualized)
Other Equity: ₹12,723.13 (as of March 31, 2026)
Research and development expenditure: ₹600.69
Segment-wise Performance:
The Group is primarily engaged in a single business segment: "Sale of Pharmaceuticals products." There are no other reportable segments as per Ind AS 108.
Corporate Actions:
- Scheme of Amalgamation approved on July 20, 2026, for Kia Health Tech Private Limited with Rubicon Research Limited under fast-track merger route (Section 233 of Companies Act, 2013)
- No accounting effect given in current results as scheme not yet effective
Other Significant Information:
- Acquisition of 85% stake in Arinna Lifesciences Limited completed on April 30, 2026, for ₹1,759.17 million
- Results include Arinna Lifesciences from acquisition date, making quarter results not comparable with previous periods
- Subsequent to quarter end: AdvaGen Holdings Inc. acquired manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC at enterprise value of USD 2.9 million
- Entities included in consolidation: Parent + 13 subsidiaries including Arinna Lifesciences Limited (from April 30, 2026)
- Four subsidiaries not reviewed by Deloitte: Total assets ₹2,266.55 million, revenue ₹647.50 million, net loss ₹142.15 million for the quarter
- Eight subsidiaries not audited: Total assets ₹1,288.78 million, revenue ₹223.68 million, net profit ₹20.43 million for the quarter